Table 1 Sociodemographic characteristics of participants who responded to the surveys
After first vaccination Comparison of vaccines | After second vaccination Comparison of vaccination regimens | After third vaccination Comparison of vaccination regimens | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
mRNA | Vector | Homologous mRNA | Homologous vector | Heterologous | Homologous PI mRNA | Homologous PI vector | Heterologous PI mRNA/vector | ||||||||
Short-term survey | |||||||||||||||
BNT | m1273 | ChAd | Ad26 | BNT- BNT | m1273 m1273 | ChAd- ChAd | ChAd-BNT | ChAd-m1273 | BNT | m1273 | BNT | m1273 | BNT | m1273 | |
N | 2044 | 687 | 177 | 155 | 5391 | 1386 | 439 | 1098 | 820 | 884 | 782 | 84 | 59 | 204 | 229 |
Gender (%) | |||||||||||||||
Female | 55.9 | 62.6 | 36.7 | 41.3 | 57.6 | 60.2 | 41.2 | 59.5 | 59.8 | 62.8 | 56.0 | 45.2 | 44.1 | 60.3 | 38.9 |
Male | 44.0 | 37.1 | 63.3 | 58.7 | 42.3 | 39.5 | 58.8 | 40.5 | 40.2 | 37.1 | 44.0 | 54.8 | 55.9 | 39.7 | 61.1 |
Divers | 0 | 0.3 | 0 | 0 | 0.1 | 0.3 | 0 | 0 | 0.1 | 0.1 | 0 | 0 | 0 | 0 | 0 |
Age | |||||||||||||||
Mean | 42.1 | 41.4 | 46.1 | 39.2 | 44.8 | 43.4 | 56.3 | 48.3 | 47.5 | 38.1 | 47.3 | 51.9 | 51.1 | 40.1 | 51.9 |
SD | 14.8 | 14.4 | 15.9 | 12.9 | 15.3 | 14.4 | 15.6 | 13.9 | 13.9 | 16.4 | 11.4 | 15.8 | 12.7 | 14.3 | 12.9 |
No pre-existing diseases (%) | |||||||||||||||
44.8 | 44.7 | 48.0 | 60.0 | 40.0 | 42.3 | 29.6 | 36.7 | 42.1 | 47.3 | 41.4 | 36.9 | 40.7 | 53.4 | 48.5 | |
m-SCQ-D | |||||||||||||||
Median | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
IQR | 0–2 | 0–2 | 0–2 | 0–2 | 0–2 | 0–2 | 0–3 | 0–2 | 0–2 | 0–2 | 0–2 | 0–2 | 0–2 | 0–1 | 0–2 |
BMI | |||||||||||||||
Mean | 25.4 | 25.7 | 25.2 | 25.1 | 25.8 | 25.8 | 26.9 | 25.8 | 25.8 | 24.7 | 25.9 | 25.7 | 28.7 | 25.1 | 26.1 |
SD | 5.4 | 5.4 | 4.3 | 4.0 | 5.4 | 5.4 | 5.2 | 5.0 | 5.3 | 5 | 5.1 | 5.1 | 5.4 | 5.4 | 4.6 |
NA | 27 | 16 | 3 | 1 | 62 | 22 | 5 | 12 | 8 | 10 | 8 | 1 | 0 | 2 | 2 |
Participants with other vaccinations 8 weeks before first/third vaccination (%) | |||||||||||||||
5.8 | 4.8 | 7.9 | 3.2 | 5.5 | 5.2 | 5.5 | 5.9 | 7.1 | 25.7 | 25.7 | 41.7 | 32.2 | 35.8 | 33.6 | |
Time between 1st and 2nd vaccination (days) | |||||||||||||||
Mean | 40.2 | 41.6 | 76.6 | 68.6 | 75.9 | ||||||||||
SD | 5.8 | 3.2 | 12.8 | 13.1 | 11.4 | ||||||||||
NA | 62 | 22 | 5 | 12 | 8 | ||||||||||
Long-term survey | |||||||||||||||
BNT | m1273 | ChAd | Ad26 | BNT- BNT | m1273 m1273 | ChAd- ChAd | ChAd-BNT | ChAd-m1273 | mRNA PI-BNT | mRNA PI-m1273 | Vector PI-BNT | Vector PI-m1273 | Het. PI-BNT | Het. PI-m1273 | |
N | 2002 | 689 | 192 | 159 | 5513 | 1378 | 426 | 1201 | 847 | 932 | 829 | 92 | 61 | 226 | 233 |
Gender (%) | |||||||||||||||
Female | 56.0 | 61.4 | 37.0 | 42.1 | 58.1 | 60.7 | 41.3 | 61.5 | 60.9 | 62.6 | 56.0 | 45.7 | 49.2 | 63.7 | 38.6 |
Male | 44.0 | 38.5 | 63.0 | 57.9 | 41.8 | 39.0 | 58.7 | 38.5 | 39.0 | 37.2 | 44.0 | 54.3 | 50.8 | 36.3 | 61.4 |
Divers | 0.0 | 0.1 | 0.0 | 0.0 | 0.1 | 0.3 | 0.0 | 0.0 | 0.1 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Age | |||||||||||||||
Mean | 44.6 | 41.7 | 48.4 | 39.7 | 45.1 | 43.9 | 57.3 | 48.5 | 48.4 | 38.4 | 47.6 | 51.7 | 50.8 | 40.3 | 51.9 |
SD | 15.3 | 14.4 | 16.2 | 12.9 | 15.3 | 14.5 | 15.6 | 13.5 | 14.1 | 16.3 | 11.3 | 15.8 | 13.0 | 14.1 | 13.0 |
No pre-existing diseases (%) | |||||||||||||||
40.0 | 44.1 | 42.2 | 61.0 | 39.8 | 41.4 | 30.0 | 37.1 | 41.8 | 47.6 | 41.4 | 37.0 | 44.3 | 52.2 | 46.8 | |
m-SCQ-D | |||||||||||||||
Median | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
IQR | 0–2 | 0–2 | 0–2 | 0–2 | 0–2 | 0–2 | 0–3 | 0–2 | 0–1 | 0–2 | 0–2 | 0–2 | 0–2 | 0–1 | 0–1,5 |
BMI | |||||||||||||||
Mean | 25.8 | 25.8 | 25.6 | 25.2 | 25.8 | 25.8 | 26.6 | 25.8 | 25.8 | 24.9 | 26.0 | 26.0 | 28.4 | 25.2 | 26.3 |
SD | 5.6 | 5.4 | 4.6 | 4.2 | 5.4 | 5.4 | 5.2 | 5.1 | 5.3 | 5.2 | 5.2 | 5.1 | 5.3 | 5.6 | 4.9 |
NA | 28 | 13 | 2 | 1 | 64 | 22 | 5 | 10 | 7 | 10 | 8 | 1 | 0 | 3 | 2 |
Participants with other vaccinations 8 weeks before first vaccination (%) | |||||||||||||||
5.7 | 4.6 | 7.3 | 3.1 | 5.5 | 5.3 | 4.9 | 6.2 | 7.3 | 25.4 | 26.7 | 42.4 | 27.9 | 35.8 | 32.2 | |
Time between 1st and 2nd vaccination (days) | |||||||||||||||
Mean | 40.2 | 41.5 | 76.6 | 68.6 | 75.9 | ||||||||||
SD | 5.8 | 3.2 | 12.8 | 13.1 | 11.4 | ||||||||||
NA | 7 | 1 | 0 | 1 | 0 | ||||||||||
Follow-up survey | |||||||||||||||
BNT | m1273 | ChAd | Ad26 | BNT- BNT | m1273 m1273 | ChAd- ChAd | ChAd-BNT | ChAd-m1273 | mRNA PI-BNT | mRNA PI-m1273 | Vector PI-BNT | Vector PI-m1273 | Het. PI-BNT | Het. PI-m1273 | |
N | 5539 | 1342 | 471 | 1382 | 879 | 916 | 796 | 94 | 60 | 207 | 233 | ||||
Gender (%) | |||||||||||||||
Female | 58.8 | 61.2 | 41.0 | 61.9 | 60.4 | 63.3 | 55.8 | 47.9 | 46.7 | 66.7 | 38.6 | ||||
Male | 41.1 | 38.5 | 59.0 | 38.1 | 39.5 | 36.6 | 44.2 | 52.1 | 52.3 | 33.3 | 61.4 | ||||
Divers | 0.1 | 0.4 | 0.0 | 0.0 | 0.1 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | ||||
Age | |||||||||||||||
Mean | 45.6 | 44.6 | 57.3 | 48.9 | 48.4 | 39.0 | 47.8 | 52.0 | 50.8 | 40.9 | 51.9 | ||||
SD | 15.2 | 14.3 | 15.4 | 13.6 | 14.3 | 16.6 | 11.4 | 15.9 | 12.6 | 14.0 | 13.0 | ||||
No pre-existing diseases (%) | |||||||||||||||
38.9 | 39.9 | 29.9 | 37.4 | 41.9 | 46.8 | 41.2 | 36.2 | 43.3 | 50.7 | 45.9 | |||||
m-SCQ-D | |||||||||||||||
Median | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||
IQR | 0–2 | 0–2 | 0–3 | 0–2 | 0–2 | 0–2 | 0–2 | 0–2 | 0–2 | 0–2 | 0–2 | ||||
BMI | |||||||||||||||
Mean | 25.8 | 25.9 | 26.8 | 25.6 | 25.9 | 24.9 | 26.0 | 25.7 | 28.2 | 25.0 | 26.2 | ||||
SD | 5.4 | 5.4 | 5.3 | 4.9 | 5.2 | 5.2 | 5.1 | 5.3 | 5.2 | 5.2 | 4.9 | ||||
NA | 59 | 21 | 6 | 14 | 1 | 10 | 8 | 1 | 0 | 3 | 2 | ||||
Participants with other vaccinations 8 weeks before first vaccination (%) | |||||||||||||||
7.2 | 4.8 | 5.1 | 6.2 | 7.3 | 26.3 | 26.6 | 40.4 | 26.7 | 37.2 | 33.5 | |||||
Time between 1st and 2nd vaccination (days) | |||||||||||||||
Mean | 40.2 | 41.6 | 76.8 | 70.5 | 77.8 | ||||||||||
SD | 6 | 3.8 | 13 | 12.9 | 10.9 | ||||||||||
NA | 6 | 0 | 0 | 0 | 0 | ||||||||||